Local QP Support for Batch Release
Ensure Quality and Compliance from Manufacturing to Market While Navigating Regulatory Challenges with Our Expert QP Solutions
We assure compliant batch release by our local expertise and global excellence
We offer top-notch local Qualified Person (QP) support for batch release; ensuring pharmaceutical products meet regulatory standards with precision and expertise. Our services are tailored to your market’s specific needs, facilitating seamless and compliant batch release processes.
When a pharmaceutical product is released into a clinical trial or the market in the European Union, it must be certified by a Qualified Person (QP). This process, known as a QP release, occurs after the drug is released. Pharmaceutical products imported into the EU from outside the EU are also subject to QP certification and release. Zenovel offers Local QP Support for Batch, and it is recommended to explore their range of activities and benefits.
Local QP Support for Batch release
Responsibilities of the Qualified Person (QP)
The QP is responsible for ensuring that pharmaceutical products meet high standards and quality attributes, regardless of the manufacturing location. According to Article 48 of Directive 2001/83/EC, the QP must certify that each batch of pharmaceutical products complies with the established quality standards. Before a product is released to the market or used in clinical trials, the QP must verify that the product adheres to GMP guidelines and that all necessary documentation is authorized. Additionally, the QP ensures that the distribution of pharmaceutical products complies with both local regulations and international laws in the respective countries.
Activities performed by our local QP support
- QP Batch Certification
- QP Batch Release
- Audits and reviews of batch records
- Provision of certificates of release
- Management of recalls, complaints, suspensions
- Batch withdrawals
- Supervision of serialization alerts
- Contact with competent healthcare authorities
- Fiscal flow-chain management
- Physical flow-chain optimization
- Logistics optimization
- Quality control assurance
- Batch expiry extension assistance.
- Additional services include audits of medicinal product manufacturing sites, Active Products Ingredient (API) manufacturing sites, support for manufacturers in EU GMP certification, scientific support for manufacturers and marketing authorization holders, regulatory affairs consultancy services, and collaboration with reliable subcontractors for analytical and microbial sample testing.
- Our services
- Why Choose Zenovel ?
- Expertise and Experience
Extensive knowledge and experience in pharmaceutical quality and regulatory affairs.
- Localized Knowledge
In-depth understanding of local regulations and market
- Quality Commitment
Dedicated to maintain highest quality standards compliance.
Ensure products are safe and effective.
- Client-oriented Approach
Work closely with clients
Provide personalized support and solutions.
People Also Ask (FAQs)
Local QP (Qualified Person) support in the EU refers to regulatory services provided by an EU-based Qualified Person responsible for certifying that a pharmaceutical product batch complies with EU GMP requirements before it is released to the European market. This certification ensures that each batch meets quality, safety, and regulatory standards.
Under EU pharmaceutical regulations, every medicinal product batch must be certified by a Qualified Person (QP) before being released for distribution. The QP verifies that manufacturing and quality control processes comply with EU GMP guidelines, ensuring product quality and regulatory compliance.
EU QP batch release support includes batch documentation review, GMP compliance verification, quality control data assessment, and Qualified Person (QP) certification. Zenovel supports these services by ensuring accurate documentation, regulatory compliance, and seamless coordination to meet EU requirements for safe and timely product release.
Local Qualified Person support for batch release in the EU helps pharmaceutical companies meet regulatory obligations required by European authorities. By ensuring proper batch certification, regulatory compliance, and GMP verification, companies can efficiently release products into the EU market.
Zenovel provides expert local QP support for batch release in the EU, including batch documentation review, EU GMP compliance verification, and QP certification services. Their regulatory experts help pharmaceutical companies streamline the EU batch release process and maintain regulatory compliance.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
